Kobayashi Hirohito, Takagi Toshio, Iizuka Junpei, Yoshida Kazuhiko, Kondo Tsunenori, Tanabe Kazunari
Department of Transfusion Medicine and Cell Processing Tokyo Women's Medical University Hospital Shinjuku, Tokyo Japan.
Department of Urology Tokyo Women's Medical University Shinjuku Tokyo Japan.
IJU Case Rep. 2018 Dec 5;2(1):37-42. doi: 10.1002/iju5.12034. eCollection 2019 Jan.
Survival among patients with metastatic renal cell carcinoma has been prolonged with advancements in treatment; however, its cure remains challenging. We describe three patients with metastatic renal cell carcinoma who showed long-term survival and discuss their response to sequential therapy.
Three patients underwent radical nephrectomy and subsequent treatment for metastatic renal cell carcinoma. They received cytokine therapy, target therapy, and an immuno-oncology drug. Metastatic growth patterns based on computed tomography scans were plotted using a line or bar graph to visualize the response to sequential therapy, and the numbers of International Metastatic renal cell carcinoma Database Consortium risk score were also calculated.
The metastatic lesions responded differently to the administered drugs, and the sum of the axis of measurable metastasis is valuable to get an overview of treatment. Furthermore, having the same or lower International Metastatic renal cell carcinoma Database Consortium risk score during sequential therapy, and long duration of each target therapy contributed to prolonged survival.
随着治疗方法的进步，转移性肾细胞癌患者的生存期得以延长；然而，治愈该病仍具有挑战性。我们描述了三名长期存活的转移性肾细胞癌患者，并讨论了他们对序贯治疗的反应。
三名患者接受了根治性肾切除术及后续转移性肾细胞癌治疗。他们接受了细胞因子治疗、靶向治疗和免疫肿瘤药物治疗。根据计算机断层扫描绘制转移生长模式的折线图或柱状图，以直观显示对序贯治疗的反应，并计算国际转移性肾细胞癌数据库联盟风险评分的数值。
转移性病变对所用药物的反应各不相同，可测量转移轴的总和对于全面了解治疗情况很有价值。此外，序贯治疗期间国际转移性肾细胞癌数据库联盟风险评分相同或更低，以及每种靶向治疗的持续时间较长，都有助于延长生存期。
